LSD1 depletion enhances tumor immunogenicity and T cell infiltration in poorly immunogenic tumors and elicits significant responses to anti-PD-1 therapy in checkpoint blockade-refractory mouse melanoma [14]. The gene discussed is KDM1A; the disease is neoplasm.